This site is intended for healthcare professionals

IDMC recommends that Phase III SALAMANDER trial of REX 001 continues in chronic limb-threatening ischemia.

Read time: 1 mins
Last updated:9th Sep 2021
Published:9th Sep 2021
Ixaka announced positive interim results of its lead REX 001 drug candidate from a Phase III clinical trial, which evaluated the safety and efficacy results 12 months after treatment with REX 001 or placebo in patients diagnosed with chronic limb-threatening ischemia (CLTI) and diabetes.
Condition: Critical Limb Ischaemia
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest